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Objective:	Glycemic	control	in	the	critically	ill	intensive	care	unit	(ICU)	patient	has	been	shown	to	
improve	morbidity	and	mortality.	We	sought	to	investigate	the	effect	of	early	glycemic	control	in	critically	ill	
emergency	department	(ED)	patients	in	a	small	pilot	trial.	
Methods: Adult	non-trauma,	non-pregnant	ED	patients	presenting	to	a	university	tertiary	referral	center	
and	identified	as	critically	ill	were	eligible	for	enrollment	on	a	convenience	basis.	Critical	illness	was	
determined	upon	assignment	for	ICU	admission.	Patients	were	randomized	to	either	ED	standard	care	
or	glycemic	control.	Glycemic	control	involved	use	of	an	insulin	drip	to	maintain	blood	glucose	levels	
between	80-140	mg/dL.	Glycemic	control	continued	until	ED	discharge.	Standard	patients	were	managed	
at	ED	attending	physician	discretion.	We	assessed	severity	of	illness	by	calculation	of	APACHE	II	score.	
The	primary	endpoint	was	in-hospital	mortality.	Secondary	endpoints	included	vasopressor	requirement,	
hospital	length	of	stay,	and	mechanical	ventilation	requirement.	
Results: Fifty	patients	were	randomized,	24	to	the	glycemic	group	and	26	to	the	standard	care	cohort.	
Four	of	the	24	patients	(17%)	in	the	treatment	arm	did	not	receive	insulin	despite	protocol	requirements.	
While	receiving	insulin,	three	of	24	patients	(13%)	had	an	episode	of	hypoglycemia.	By	chance,	the	
patients	in	the	treatment	group	had	a	trend	toward	higher	acuity	by	APACHE	II	scores.	Patient	mortality	
and	morbidity	were	similar	despite	the	acuity	difference.	
Conclusion: There	was	no	difference	in	morbidity	and	mortality	between	the	two	groups.	The	benefit	of	
glycemic	control	may	be	subject	to	source	of	illness	and	to	degree	of	glycemic	control,	or	have	no	effect.	
Such	questions	bear	future	investigation.	[West	J	Emerg	Med.	2010;	11(1):20-23].
INTRODUCTION
The critical care patient population is presenting more 
frequently to the emergency department (ED).1 Accordingly, 
critical care interventions are becoming a routine part of ED 
practice, 2 and it is a logical progression to investigate the 
delivery of proven critical care therapies to critically ill ED 
patients.
Glycemic control in critically ill patients in the intensive 
care unit (ICU) has been shown to attenuate both morbidity 
and mortality.3-5 Early therapeutic intervention in critical care 
patients has been shown to yield the greatest improvement 
in patient outcomes.6, 7 The concept of early intervention 
and glycemic control makes the ED an opportune arena for 
study. There is controversy regarding the efficacy of glycemic 
control. One current study challenging its practice did not 
have adequate power to support the discontinuation of this 
practice.8 The most recent study discourages intensive control, 
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guidelines.9 Glycemic control remains an option in the 
Surviving Sepsis Campaign.10
Extrapolation of the concept of glycemic control from 
the ICU to the ED may have the potential for added benefit. 
To address this, we conducted a randomized prospective pilot 
study that, to our knowledge, is the first effort to investigate 
the effect of early management of blood glucose in critically 
ill ED patients. 
METHODS
This was a local institutional review committee-approved 
study of critically ill adult patients presenting to ED at the 
University of Massachusetts Medical School, a tertiary 
referral center with approximately 75,000 adult visits per 
year. The University ED has a 25% inpatient admission 
rate, and 20% of these are admitted to the ICU. We enrolled 
a convenience sample between December 2004 and April 
2006. Inclusion criteria were: age > 18 years; critical 
illness (based on assignment to the ICU by a board-certified 
ED attending physician); and ability to obtain informed 
consent from the patient or surrogate. Prospective exclusion 
criteria were trauma-related illness; diabetic ketoacidosis 
or hyperosmolar hyperglycemic nonketotic coma; insulin 
allergy; overdoses involving hypoglycemic agents, beta-
blockers or calcium channel antagonists; pregnancy, 
incarceration; and inability to obtain informed consent. 
Trauma patients have service specific protocols that would 
not permit inclusion in this study. 
Consented patients were randomized to standard 
ED therapy or glycemic control. To maintain allocation 
concealment, patients were randomized by opening a sealed 
envelope determining patient’s group assignment after 
consent was obtained. Standard ED care was based on glucose 
management at the discretion of the attending physician. 
Patients randomized to glycemic control were managed with a 
standardized order sheet and nurse-driven protocol developed 
by the investigators specifically for the study. The goal of the 
protocol was to reach and maintain a blood glucose level of 
80-140 mg/dL. Glycemic control patients had bedside whole 
blood glucose levels checked every 1-2 hours. Patients with 
glucose levels greater than 140 mg/dL were placed on an 
insulin drip (prepared off-site at a standard concentration by 
the hospital pharmacy), bedside glucose levels were checked 
every hour, and the drip rate was adjusted based on glucose 
levels. The standard protocol order sheet provided for drip 
cessation for glucose levels < 80 mg/dL. Hypoglycemia 
(glucose levels < 60 mg/dL) was treated with a 50 ml of 50% 
dextrose in water. The insulin drip was temporarily stopped 
when the patient left the ED for testing and was permanently 
discontinued at the time of discharge from the ED.
We reviewed charts from all enrolled patients. The 
primary endpoint of the study was in-hospital mortality. 
Secondary endpoints included hospital length of stay, 
vasopressor use, mechanical ventilator days, transfusion 
requirement, and renal failure requiring dialysis. Patient 
demographics and APACHE II (Acute Physiology and 
Chronic Health Evaluation) scores were recorded. 
Continuous variables are reported as mean + SEM and 
compared between the glycemic control versus standard 
care groups by Student t-test. Categorical variables are 
presented as percentage of total and compared between 
groups by Fisher’s exact test.
RESULTS
We identified 66 patients as eligible for the study. 
Fourteen patients or their families declined, one patient was 
legally incompetent to consent and did not have a guardian 
present, and one patient was not offered treatment at the 
discretion of the ED physician. The remaining 50 patients 
were successfully consented and enrolled, with 26 assigned 
to receive standard therapy and 24 to glycemic control.
In the standard treatment arm, 19 of 26 patients (73%) 
presented with serum glucose greater than 140 mg/dL. Five of 
these 19 (26%) were managed by the ED with insulin therapy. 
Four received intravenous boluses of insulin, while one patient 
with sepsis was placed on an insulin drip. Insulin was initiated 
for these five patients in response to high glucose levels. Mean 
glucose for this cohort was 302 + 127. 
In the glycemic control arm, 10 of the 24 randomized 
patients (42%) had initial glucose values >140 mg/dL. The 
difference in initial glucose level between the standard 
and glycemic control cohort was statistically significant 
(p=0.04). Four patients had a glucose of >140 mg/dL and 
did not receive treatment per protocol at any time. These 
patients were included in the analysis on an intention-
to-treat basis. Of the 24 patients in the glycemic control 
group, 16 (67%) achieved the glucose values within 80-
140 mg/dL target. There was a trend toward a reduction in 
blood glucose levels in the 24 patients assigned to receive 
glycemic control versus the standard therapy (167 + 14 
versus 210 + 22 mg/dL; p=0.11).
Four of 24 patients randomized to glycemic control 
(17%) experienced one episode of hypoglycemia. While 
three of 24 patients (13%) were actually receiving insulin 
at the time of the event, one of the four patients developed 
hypoglycemia without insulin therapy, presumably as a 
function of his illness. No hypoglycemic events occurred in 
the standard therapy group (p=0.05). 
Demographics and in-hospital outcome
Both groups were well matched for age and gender. 
Despite randomization, there was a trend toward higher 
APACHE II scores in the treatment group as opposed to 
controls: mean scores of 17.2 + 1.5 in the treatment group 
versus 14.7 + 1.3 for the standard therapy group (p=0.20). 
Hospital length of stay trended toward a longer duration in 
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the glycemic control group (Table 1). The requirement for 
intubation, vasopressors, transfusion and dialysis were similar 
in the two cohorts (Table 1). There was a higher percentage 
of patients with diabetes mellitus, based on past medical 
history in the standard treatment group (9/26 [35%]), as 
opposed to the glycemic control group (4/24 [17%]) (p=0.20). 
Critical care diagnoses were variable, ranging from sepsis to 
gastrointestinal bleed (Table 2).
DISCUSSION
The ED offers an opportunity for early intervention 
as it is frequently the first point of entry for the critically 
ill patient population.6,7 This pilot study represents, to our 
knowledge, the first attempt to administer early glycemic 
control in the ED.
Multiple logistic issues in the ED may limit the ability 
to deliver critical care therapies, including management 
of blood glucose. The onset of therapy may be delayed or 
deferred in instances in which patient volumes are high and 
nursing resources limited. In four patients enrolled in the 
current study, insulin per protocol was not administered 
despite randomization to the intensive glycemic control 
group. Conversely, four patients had hypoglycemia in 
the treatment arm. We hypothesize that these protocol 
violations and complications may have occurred at times of 
high ED volume and nursing workload. 
We hypothesize that the ED environment also 
provided a barrier to successful glycemic goals. Insulin 
drip initiation or glucose level monitoring may have been 
delayed due to high nursing workload. Insulin drip delivery 
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Table 1. Demographics	and	in-hospital	outcome
Standard
Therapy
(n=26)
Intensive
Glycemic Control
(n=20)
Age	(years) 58+4 60+4 p=ns
Gender	(%	male) 15/26	(58%) 7/20	(35%) p=ns
Acute	Physiology	and	Chronic	Health	Evaluation	II	Score 14.7+1.3 17.3+1.5 p=0.20	(ns)
Prevalence	of	diabetes 9/26	(35%) 3/20	(15%) p=0.18	(ns)
ED	length	of	stay	(hours) 13.4+1.7 17.4+3.9 p=0.31	(ns)
Hospital	length	of	stay	(days) 10.4+2.1 15.6+3.8 p=0.20	(ns)
Intubated 13/26	(50%) 10/20	(50%) p=ns
Required	vasopressors 11/26	(42%) 9/20	(45%) p=ns
Duration	of	vasopressors	(hours) 102	+	57 196	+	133 p=ns
Required	transfusion 13/26	(50%) 8/20	(40%) p=ns
Required	dialysis	 2/26	(8%) 2/20	(10%) p=ns
Incidence	of	blood	infection 4/26	(15%) 4/20	(20%) p=ns
Mortality 6/26	(23%) 4/20	(20%) p=ns
Table 2.	Patient	diagnoses
Standard
Therapy
(n=26)
Intensive
Glycemic Control
(n=24)
Sepsis 6/26	(23%) 10/24	(42%)
Gastrointestinal	bleed 5/26	(19%) 1/24	(4%)
Acute	coronary	syndrome 3/26	(12%) 0/24	(0%)
Toxic	ingestion 2/26	(8%) 2/24	(8%)
Pulmonary	embolus 1/26	(4%) 2/24	(8%)
Congestive	heart	failure 1/26	(4%) 2/24	(8%)
Chronic	obstructive	pulmonary	disease/asthma	Exacerbation 2/26	(8%) 1/24	(4%)
Hemorrhagic/ischemic	stroke 1/26	(4%) 1/24	(4%)
Hepatic	failure 0/26	(0%) 2/24	(8%)
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from the pharmacy may have added to treatment delay. 
Patients also were transferred to the ICU prior to successful 
completion of the glycemic protocol. Average transfer time 
to the ICU during the study period was 15 hours, with a 
range of 2 -72 hours.
Despite these challenges, we report that 24 critically 
ill patients with high APACHE II scores were treated with 
a glycemic control protocol, and in 16 of these 24 patients 
the goal of successful glycemic control was achieved. 
Hypoglycemia did occur, but we did not measure a 
resultant increase in hospital mortality. We acknowledge 
again that the study population is too small to appreciate a 
significant mortality effect from hypoglycemia.
There was a trend toward higher acuity in the glycemic 
control group with equivalent mortality, but this trend was 
not statistically significant. Hypoglycemia in the treatment 
group presented a challenge as in other studies.8, 9 The risk 
of hypoglycemia in the ED environment can be of greater 
consequence as it may not be recognized as quickly as in 
a more controlled ICU. Further evaluation of glycemic 
control in the ED should provide for stringent precautions 
for hypoglycemia.
LIMITATIONS 
Conclusions regarding the potential benefits of early 
insulin therapy initiated in the ED are precluded by the 
small sample size. Our study was not powered to discern a 
difference in mortality, hospital length of stay, vasopressor 
use, mechanical ventilator days, transfusion requirement, or 
renal failure requiring dialysis. 
CONCLUSION
The NICE-SUGAR investigators have confirmed the 
lack of utility of intensive glycemic control as well as 
increased hypoglycemia risk.9 Questions regarding range 
of glucose control and appropriate critical care patient 
population remain unanswered. Larger-scale, randomized 
protocols should be considered in order to pursue this 
concept and establish whether early management of blood 
glucose in the ED will improve patient outcome.
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